BioInvent International AB (publ) (BINV.ST)
SEK 27.3
(9.2%)
SEK 27.3
(9.2%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 441.4 Million SEK | 12.93% |
| 2022 | 376.59 Million SEK | 26.57% |
| 2021 | 297.54 Million SEK | 33.83% |
| 2020 | 222.32 Million SEK | -3.65% |
| 2019 | 230.74 Million SEK | 42.76% |
| 2018 | 161.63 Million SEK | 9.68% |
| 2017 | 147.36 Million SEK | 9.55% |
| 2016 | 134.52 Million SEK | 20.61% |
| 2015 | 111.53 Million SEK | 9.51% |
| 2014 | 101.85 Million SEK | 1.34% |
| 2013 | 100.5 Million SEK | -57.11% |
| 2012 | 234.31 Million SEK | 19.36% |
| 2011 | 196.3 Million SEK | -6.83% |
| 2010 | 210.7 Million SEK | -19.01% |
| 2009 | 260.16 Million SEK | 5.94% |
| 2008 | 245.56 Million SEK | 47.9% |
| 2007 | 166.03 Million SEK | 2.01% |
| 2006 | 162.76 Million SEK | -4.5% |
| 2005 | 170.44 Million SEK | 8.73% |
| 2004 | 156.75 Million SEK | -6.39% |
| 2003 | 167.46 Million SEK | 12.04% |
| 2002 | 149.46 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 115.45 Million SEK | -19.08% |
| 2024 Q1 | 90.97 Million SEK | -25.54% |
| 2024 Q2 | 148.19 Million SEK | 62.89% |
| 2023 Q3 | 108.27 Million SEK | -1.43% |
| 2023 Q2 | 109.84 Million SEK | 13.02% |
| 2023 Q1 | 97.19 Million SEK | -2.27% |
| 2023 FY | 425.28 Million SEK | 12.93% |
| 2023 Q4 | 122.17 Million SEK | 12.83% |
| 2022 Q2 | 105.12 Million SEK | 23.75% |
| 2022 FY | 376.59 Million SEK | 26.57% |
| 2022 Q4 | 99.45 Million SEK | 14.22% |
| 2022 Q3 | 87.07 Million SEK | -17.17% |
| 2022 Q1 | 84.94 Million SEK | 1.65% |
| 2021 Q4 | 83.56 Million SEK | 27.73% |
| 2021 Q2 | 62.39 Million SEK | -27.59% |
| 2021 FY | 297.54 Million SEK | 33.83% |
| 2021 Q3 | 65.42 Million SEK | 4.85% |
| 2021 Q1 | 86.16 Million SEK | 25.21% |
| 2020 Q1 | 49.68 Million SEK | -23.56% |
| 2020 Q2 | 54.74 Million SEK | 10.19% |
| 2020 Q4 | 68.81 Million SEK | 40.22% |
| 2020 Q3 | 49.08 Million SEK | -10.35% |
| 2020 FY | 222.32 Million SEK | -3.65% |
| 2019 Q1 | 45.11 Million SEK | 5.21% |
| 2019 FY | 230.74 Million SEK | 42.76% |
| 2019 Q3 | 55.05 Million SEK | -16.04% |
| 2019 Q4 | 64.99 Million SEK | 18.06% |
| 2019 Q2 | 65.56 Million SEK | 45.32% |
| 2018 Q1 | 36.65 Million SEK | -24.54% |
| 2018 Q2 | 53.31 Million SEK | 45.44% |
| 2018 FY | 161.63 Million SEK | 9.68% |
| 2018 Q3 | 29.41 Million SEK | -44.83% |
| 2018 Q4 | 42.88 Million SEK | 45.81% |
| 2017 Q4 | 48.57 Million SEK | 69.88% |
| 2017 Q3 | 28.59 Million SEK | -18.37% |
| 2017 Q1 | 35.15 Million SEK | -6.3% |
| 2017 FY | 147.36 Million SEK | 9.55% |
| 2017 Q2 | 35.02 Million SEK | -0.36% |
| 2016 FY | 134.52 Million SEK | 20.61% |
| 2016 Q3 | 29.39 Million SEK | -22.46% |
| 2016 Q2 | 37.9 Million SEK | 27.6% |
| 2016 Q1 | 29.7 Million SEK | -14.96% |
| 2016 Q4 | 37.52 Million SEK | 27.66% |
| 2015 Q4 | 34.93 Million SEK | 40.81% |
| 2015 FY | 111.53 Million SEK | 9.51% |
| 2015 Q3 | 24.8 Million SEK | -14.41% |
| 2015 Q2 | 28.98 Million SEK | 27.08% |
| 2015 Q1 | 22.81 Million SEK | -18.55% |
| 2014 Q2 | 29.06 Million SEK | 32.04% |
| 2014 Q4 | 28 Million SEK | 23.03% |
| 2014 Q1 | 22.01 Million SEK | -24.63% |
| 2014 FY | 101.85 Million SEK | 1.34% |
| 2014 Q3 | 22.76 Million SEK | -21.69% |
| 2013 Q4 | 29.21 Million SEK | 28.37% |
| 2013 Q2 | 22.49 Million SEK | -13.64% |
| 2013 FY | 100.5 Million SEK | -57.11% |
| 2013 Q1 | 26.04 Million SEK | -24.41% |
| 2013 Q3 | 22.75 Million SEK | 1.16% |
| 2012 Q1 | 52.07 Million SEK | -17.11% |
| 2012 Q3 | 50.64 Million SEK | -49.1% |
| 2012 Q4 | 34.45 Million SEK | -31.96% |
| 2012 FY | 234.31 Million SEK | 19.36% |
| 2012 Q2 | 99.5 Million SEK | 91.09% |
| 2011 Q4 | 62.82 Million SEK | 41.0% |
| 2011 Q3 | 44.55 Million SEK | -11.81% |
| 2011 Q2 | 50.52 Million SEK | 31.89% |
| 2011 Q1 | 38.3 Million SEK | -22.13% |
| 2011 FY | 196.3 Million SEK | -6.83% |
| 2010 FY | 210.7 Million SEK | -19.01% |
| 2010 Q4 | 49.19 Million SEK | 29.13% |
| 2010 Q3 | 38.09 Million SEK | -46.57% |
| 2010 Q2 | 71.29 Million SEK | 35.76% |
| 2010 Q1 | 52.51 Million SEK | -20.51% |
| 2009 Q3 | 56.31 Million SEK | -13.59% |
| 2009 Q2 | 65.17 Million SEK | -10.95% |
| 2009 FY | 260.16 Million SEK | 5.94% |
| 2009 Q4 | 66.06 Million SEK | 17.32% |
| 2009 Q1 | 73.18 Million SEK | 0.0% |
| 2008 FY | 245.56 Million SEK | 47.9% |
| 2007 FY | 166.03 Million SEK | 2.01% |
| 2006 FY | 162.76 Million SEK | -4.5% |
| 2005 FY | 170.44 Million SEK | 8.73% |
| 2004 FY | 156.75 Million SEK | -6.39% |
| 2003 FY | 167.46 Million SEK | 12.04% |
| 2002 FY | 149.46 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 70.85% |
| Camurus AB (publ) | 1.05 Billion SEK | 58.345% |
| Mendus AB (publ) | 129.13 Million SEK | -241.81% |
| Lipum AB (publ) | 37.3 Million SEK | -1083.164% |
| NextCell Pharma AB | -576.01 Thousand SEK | 76729.938% |
| Simris Alg AB (publ) | 38.64 Million SEK | -1042.288% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -1458.278% |
| Active Biotech AB (publ) | 44.8 Million SEK | -885.077% |
| Amniotics AB (publ) | 29.07 Million SEK | -1418.31% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -2912.373% |
| BioArctic AB (publ) | 89.62 Million SEK | -392.489% |
| Cantargia AB (publ) | 290.01 Million SEK | -52.199% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -1915.999% |
| CombiGene AB (publ) | 44.14 Million SEK | -899.914% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | -208.701% |
| Genovis AB (publ.) | 88.19 Million SEK | -400.474% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -283.585% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -5973.239% |
| Intervacc AB (publ) | 79.78 Million SEK | -453.241% |
| Kancera AB (publ) | 63.07 Million SEK | -599.784% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -7897.88% |
| LIDDS AB (publ) | 27.75 Million SEK | -1490.527% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -5984.96% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -224.771% |
| OncoZenge AB (publ) | 15.9 Million SEK | -2675.247% |
| Saniona AB (publ) | 1.07 Million SEK | -40884.494% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | -37.292% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | -23.427% |
| Xintela AB (publ) | 57.31 Million SEK | -670.122% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | -142.884% |
| Ziccum AB (publ) | 27.87 Million SEK | -1483.338% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -2591.318% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | -43.737% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -935.38% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -2396.2% |
| Corline Biomedical AB | 30.16 Million SEK | -1363.15% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -660.633% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -430.73% |
| Aptahem AB (publ) | 10.01 Million SEK | -4308.324% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -227.708% |
| Fluicell AB (publ) | 28.61 Million SEK | -1442.45% |
| Biovica International AB (publ) | 133.72 Million SEK | -230.09% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -2130.435% |
| AcouSort AB (publ) | 25.87 Million SEK | -1605.839% |
| Abliva AB (publ) | 27.86 Million SEK | -1484.02% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | -128.115% |
| 2cureX AB (publ) | 36.51 Million SEK | -1108.727% |
| I-Tech AB | 40.14 Million SEK | -999.44% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 48.641% |
| Cyxone AB (publ) | 28.21 Million SEK | -1464.482% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -303.594% |
| Biosergen AB | 26.8 Million SEK | -1546.473% |
| Nanologica AB (publ) | 69.88 Million SEK | -531.595% |
| SynAct Pharma AB | 224.49 Million SEK | -96.62% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -899.192% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -1742.69% |
| Alzinova AB (publ) | 36.39 Million SEK | -1112.779% |
| Oncopeptides AB (publ) | 289.74 Million SEK | -52.341% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -5518.481% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -297.969% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -2902.741% |